Amikacin

Summary

Amikacin (CHEMBL177) is an approved small-molecule antimicrobial agent (ATC S01AA21); indicated across 12 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01AA21 (+2 more)
• Indications: 12 conditions
• Clinical trials: 41
• Chemistry: 585.6 Da · C22H43N5O13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL177
Name	Amikacin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	37768
ChEBI	CHEBI:2637
ATC	S01AA21, D06AX12, J01GB06
Molecular formula	C22H43N5O13
Molecular weight	585.6
InChIKey	LKCWBDHBTVXHDL-RMDFUYIESA-N

SMILES: C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N

IUPAC name: (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide

ChEBI definition: An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.

Pharmacological roles (ChEBI): antimicrobial agent, antibacterial drug, nephrotoxic agent.

Also known as: Amikacin, Amikacina, Amikacine, Amikacinum, Lukadin, NSC-177001, Potentox, amikacin, SID29215141, AMIKACINE, SID144204752, SID170465345

Parent form; salt/anhydrous children: CHEMBL1164318, CHEMBL1879513, CHEMBL4208954, CHEMBL4303360

Patent coverage: 14,565 distinct patent families (50,479 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.8	Potency	158.5	nM	CHEMBL_ACT_3621776

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
bacterial pneumonia	3	MONDO:0004652	EFO:1001272
mycobacterial infectious disease	3	MONDO:0020590	EFO:0009429
cystic fibrosis	3	MONDO:0009061	MONDO:0009061
pneumonia	2	MONDO:0005249	EFO:0003106
tuberculosis	2	MONDO:0018076	MONDO:0018076
lung disorder	2	MONDO:0005275	EFO:0003818
chronic obstructive pulmonary disease	0	MONDO:0005002	EFO:0000341
osteomyelitis	0	MONDO:0005246	EFO:0003102
urinary tract infection	0	MONDO:0100338	EFO:0003103

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 41.

Phase distribution

Phase	Trials
Not specified	16
PHASE4	8
PHASE2	7
PHASE1	4
PHASE2/PHASE3	2
PHASE3	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06808074	PHASE4	RECRUITING	A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis
NCT01659866	PHASE4	COMPLETED	Antibiotic Prophylaxis for Transrectal Prostate Biopsy
NCT02081963	PHASE4	COMPLETED	Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
NCT02365272	PHASE4	COMPLETED	Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department
NCT02872272	PHASE4	TERMINATED	Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population
NCT04197739	PHASE4	UNKNOWN	Fixed-dose Amikacin for Elderly UTI
NCT04948463	PHASE4	COMPLETED	Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
NCT07369336	PHASE4	COMPLETED	Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia
NCT04310930	PHASE2/PHASE3	RECRUITING	Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
NCT00861315	PHASE2/PHASE3	UNKNOWN	Pharmacokinetics of Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation
NCT01867138	PHASE3	COMPLETED	Neonatal Suspected Sepsis Treated With Cefazolin or Vancomycin
NCT03149640	PHASE3	COMPLETED	Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia
NCT07485010	PHASE2	NOT_YET_RECRUITING	Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
NCT00786305	PHASE2	COMPLETED	Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
NCT01004445	PHASE2	COMPLETED	A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)
NCT01528930	PHASE2	WITHDRAWN	Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease
NCT04209192	PHASE2	COMPLETED	Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)
NCT05555303	PHASE2	UNKNOWN	Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
NCT06602557	PHASE2	UNKNOWN	a Randomized Pilot Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation (ECMO-VA).
NCT07228702	PHASE1	ENROLLING_BY_INVITATION	Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
NCT02709265	PHASE1	COMPLETED	Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers
NCT02897869	PHASE1	COMPLETED	DDI Study to Investigate Interaction Between Amikacin and POL7080
NCT06238856	PHASE1	COMPLETED	Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
NCT05761405	EARLY_PHASE1	UNKNOWN	Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis
NCT06097767	EARLY_PHASE1	UNKNOWN	the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy
NCT03825874	Not specified	RECRUITING	Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children
NCT05227937	Not specified	RECRUITING	Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
NCT06426836	Not specified	RECRUITING	Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
NCT00042289	Not specified	COMPLETED	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
NCT00950222	Not specified	COMPLETED	Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic
NCT01290003	Not specified	COMPLETED	Role of Antibiotics in Preventing Infection in Babies Born Through Meconium Stained Liquor
NCT02201082	Not specified	COMPLETED	Evaluation of the Timing of the Nebulization Related to the Physiotherapy Session
NCT02489955	Not specified	UNKNOWN	Antibiotic Nephrotoxicity in Adult Patients With Cystic Fibrosis
NCT02535130	Not specified	UNKNOWN	Evaluation of Nebulization and Positive Expiratory Pressure Combination
NCT02574130	Not specified	COMPLETED	Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria
NCT02728518	Not specified	COMPLETED	Nebulized Amikacin Versus Intravenous Amikacin in the Treatment of Nosocomial Pneumonia
NCT03169114	Not specified	TERMINATED	Raja Isteri Pengiran Anak Saleha Appendicitis Treatment Without Operation
NCT04132115	Not specified	UNKNOWN	Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)
NCT04470973	Not specified	UNKNOWN	Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.
NCT04867135	Not specified	COMPLETED	Population Pharmacokinetics of Amikacin in Neonates

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kana	CPIC	MT-RNR1		yes

PharmGKB also curates 1 clinical and 6 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).